Drug Study

The Use of a Novel Drug in the Treatment of Atopic Dermatitis

I have recently been asked by a French company to trial a novel product in the treatment of atopic dermatitis. This product is a tyrosine kinase inhibitor. Tyrosine kinase is involved in mast cell growth and differentiation. Mast cell degranulation is an important part in the aetiopathogenesis of atopic dermatitis. This drug has also an action against mast cell tumours but the study I am involved in is purely for dogs with atopic dermatitis that fulfil certain criterion which are specified in the following atopic dermatitis attachments.

I would encourage vets who think that they have dogs who fulfil this atopic dermatitis criterion to consider to refer to me for screening and , if possible, inclusion onto the scheme. Please consider if the atopic dermatitis client is dedicated enough to see this through and be aware that 33% of the dogs are put on placebo.

I am more than happy to discuss the atopic dermatitis study in more detail with any vets who wish to refer a case. Please phone 0151 548 6826 or email me via the submission page or at Anthony@theskinvet.co.uk

WANTED: Dogs With Atopic Dermatitis Over 1 Year of Age

As part of an atopic dermatitis study evaluating an investigational drug for the treatment of pruritus in dogs with non-seasonal atopy.

Requirements: Dog’s with atopic dermatitis with at least 3 of the 5 following criteria:

  1. 1st symptoms began between 6 mo. and 3 years.
  2. Corticosteroid responsive, non-seasonal pruritus.
  3. Bilateral otitis externa.
  4. Bilateral erythematous interdigital pododermatitis
  5. Cheilitis (peri-oral inflammation).

Criteria:

  1. Must have adequate organ function.
  2. Must be on monthly flea control (adulticide & insect growth regulator).
  3. No diet or fatty acid supplement changes 4 weeks prior to study.
  4. No known allergies to food.
  5. No antihistamines 1 week prior to evaluation.
  6. No active skin or ear infections and must be off antibiotics and anti-fungals 2 weeks prior to evaluation.
  7. Immunotherapy must be discontinued 4 weeks prior to pre-screening.

(Acceptance for this atopic dermatitis study is based on pre-screening evaluation)

What Do Pet Owners Have To Do?

Bring their dog in for examination, blood and urinary testing every two weeks and administer daily medication.

What Do Pet Owners Receive?

All atopic dermatitis evaluations, testing and medications will be paid for by investigators (including intradermal allergy testing) after initial screening allowing them to come into the trial

This study is being conducted by Mr Anthony Chadwick BVSc CertVD MRCVS.

For more information on this atopic dermatitis study please contact Anthony@theskinvet.co.uk or 01515486826.

Plaquette